Kronos Bio Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 8

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $59.7M

Kronos Bio General Information

Description

Operator of a clinical-stage biopharmaceutical company intended to discover and develop novel cancer therapeutics. The company specializes in the discovery and development of small-molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 301 Binney Street
  • 2nd Floor East
  • Cambridge, MA 02142
  • United States
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Acquirer
Concentra Biosciences
Vertical(s)
Corporate Office
  • 301 Binney Street
  • 2nd Floor East
  • Cambridge, MA 02142
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kronos Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 01-May-2025 $59.7M Completed Generating Revenue
5. IPO 09-Oct-2020 Completed Generating Revenue
4. Early Stage VC 24-Aug-2020 Completed Generating Revenue
3. Early Stage VC (Series A) 18-Jul-2019 Completed Generating Revenue
2. Seed Round 23-May-2018 $18M $18M Completed Generating Revenue
1. Seed Round 02-Jun-2017 Completed Generating Revenue
To view Kronos Bio’s complete valuation and funding history, request access »

Kronos Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Seed
To view Kronos Bio’s complete cap table history, request access »

Kronos Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a clinical-stage biopharmaceutical company intended to discover and develop novel cancer therapeutics. The c
Biotechnology
Cambridge, MA
8 As of 2025

La Jolla, CA
 

San Diego, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Kronos Bio Competitors (41)

One of Kronos Bio’s 41 competitors is Inhibrx, a Formerly VC-backed company based in La Jolla, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Inhibrx Formerly VC-backed La Jolla, CA
Cullgen Formerly VC-backed San Diego, CA
Adimab Venture Capital-Backed Lebanon, NH
Sangamo Therapeutics Formerly VC-backed Richmond, CA
Sareum Holdings Corporation Cambridge, United Kingdom
You’re viewing 5 of 41 competitors. Get the full list »

Kronos Bio Patents

Kronos Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026222092-A1 Lysine acetyl-transferase inhibitor solid form compositions Pending 15-Apr-2025
WO-2026222104-A1 Lysine acetyl-transferase inhibitor solid form compositions Pending 15-Apr-2025
EP-4836782-A1 Lysine acetyltransferase inhibitors Pending 05-Jan-2024
WO-2025147670-A1 Lysine acetyltransferase inhibitors Inactive 05-Jan-2024
EP-4795045-A1 Lysine acetyltransferase inhibitors Pending 16-Oct-2023 C07D471/04
To view Kronos Bio’s complete patent history, request access »

Kronos Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kronos Bio Former Investors (22)

Investor Name Investor Type Holding Investor Since Participating Rounds
Angel (individual) Minority
Bellco Capital PE/Buyout Minority
BlackRock Asset Manager Minority
Casdin Capital Venture Capital Minority
Citadel Enterprise Americas Hedge Fund Minority
You’re viewing 5 of 22 investors. Get the full list »

Kronos Bio Investments (2)

Kronos Bio’s most recent deal was a Early Stage VC with RabbitX for . The deal was made on 07-Oct-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
RabbitX 07-Oct-2021 Early Stage VC Other Financial Services
Gilead (SYK Inhibitor Portfolio) 16-Jul-2020 Corporate Asset Purchase Buildings and Property
To view Kronos Bio’s complete investments history, request access »

Kronos Bio ESG

Risk Overview

Risk Rating

Updated March, 31, 2026

38.32 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,271

Rank

Percentile

Pharmaceuticals

Industry

of 908

Rank

Percentile

Pharmaceuticals

Subindustry

of 406

Rank

Percentile

To view Kronos Bio’s complete esg history, request access »

Kronos Bio FAQs

  • When was Kronos Bio founded?

    Kronos Bio was founded in 2017.

  • Where is Kronos Bio headquartered?

    Kronos Bio is headquartered in Cambridge, MA.

  • What is the size of Kronos Bio?

    Kronos Bio has 8 total employees.

  • What industry is Kronos Bio in?

    Kronos Bio’s primary industry is Biotechnology.

  • Is Kronos Bio a private or public company?

    Kronos Bio is a Private company.

  • What is the current valuation of Kronos Bio?

    The current valuation of Kronos Bio is .

  • What is Kronos Bio’s current revenue?

    The current revenue for Kronos Bio is .

  • How much funding has Kronos Bio raised over time?

    Kronos Bio has raised $528M.

  • Who are Kronos Bio’s investors?

    , Bellco Capital, BlackRock, Casdin Capital, and Citadel Enterprise Americas are 5 of 22 investors who have invested in Kronos Bio.

  • Who are Kronos Bio’s competitors?

    Inhibrx, Cullgen, Adimab, Sangamo Therapeutics, and Sareum Holdings are some of the 41 competitors of Kronos Bio.

  • When was Kronos Bio acquired?

    Kronos Bio was acquired on 01-May-2025.

  • Who acquired Kronos Bio?

    Kronos Bio was acquired by Concentra Biosciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process